We are live on ! Find out more
IPSC icon

Century Therapeutics

64 hedge funds and large institutions have $61M invested in Century Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 20 increasing their positions, 24 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

2% more funds holding

Funds holding: 6364 (+1)

1.42% less ownership

Funds ownership: 33.8%32.38% (-1.4%)

12% less capital invested

Capital invested by funds: $69.5M → $61M (-$8.5M)

17% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 24

Holders
64
Holders Change
+1
Holders Change %
+1.59%
% of All Funds
1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
20
Reduced
24
Closed
4
Calls
$4K
Puts
Net Calls
+$4K
Net Calls Change
-$15K

IPSC Hedge Fund Activity: Q2 2023 in Review

64 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q2 2023, worth a combined $61M — down 12% from $69.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IPSC positions and 4 closed out — a net gain of 1 holder — while 20 added to existing stakes and 24 trimmed.

The largest buyer was BlackRock, adding an estimated $657K. The largest seller was Federated Hermes, cutting an estimated $1.77M.

  • 64 institutional investors held Century Therapeutics (IPSC) as of Q2 2023, up from 63 in Q1 2023.
  • Funds reported $61M of Century Therapeutics stock for Q2 2023, down 12% quarter-over-quarter.
  • 5 funds opened new Century Therapeutics positions in Q2 2023 and 4 closed out, a net change of +1 holder.
  • The largest Century Therapeutics buyer in Q2 2023 was BlackRock, an estimated $657K added.
  • The largest Century Therapeutics seller in Q2 2023 was Federated Hermes, an estimated $1.77M sold.

Based on aggregated 13F filings for Q2 2023.